GlassScriptPhysician profile
Steven Cohen
NPI 1538136833
$36,033.28
in general payments reported to CMS, 2019-2025
21 companies · $11K in 2025
The $11K reported for 2025 was more than what 82% of Medical Oncology providers received nationally (typical 2025 total: $1,158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $74.37 · 2020: $1,500 · 2021: $6,220 · 2022: $6,235 · 2023: $1,228 · 2024: $9,926 · 2025: $11K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $17K · Honoraria: $3,510 · Food and Beverage: $1,156 · Travel and Lodging: $150 · Education: $43.25.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $17,145.00 |
| Honoraria | $3,510.00 |
| Food and Beverage | $1,155.53 |
| Travel and Lodging | $150.00 |
| Education | $43.25 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $7,812.50 | 2021-2025 | |
| Merck Sharp & Dohme LLC | $5,005.00 | 2020-2024 | |
| E.R. Squibb & Sons, L.L.C. | $3,962.84 | 2019-2025 | Opdivo |
| Deciphera Pharmaceuticals INC. | $3,711.97 | 2024 | Qinlock |
| Takeda Pharmaceuticals U.S.A., INC. | $2,760.00 | 2024 | Fruzaqla |
| Helsinn Therapeutics (U.S.), INC. | $2,720.00 | 2021 | |
| Astrazeneca Pharmaceuticals LP | $2,043.25 | 2025 | Enhertu |
| Taiho Oncology, INC. | $1,950.00 | 2025 | |
| Ipsen Biopharmaceuticals, INC | $1,550.00 | 2021 | |
| Seagen INC. | $1,375.00 | 2022 | |
| Incyte Corporation | $1,165.74 | 2023-2025 | Zynyz, Pemazyre |
| Bayer Healthcare Pharmaceuticals INC. | $1,027.50 | 2023 | |
| Tempus Ai, INC | $381.17 | 2024-2025 | Xt Cdx |
| Boston Scientific Corporation | $144.38 | 2024 | Therasphere Y90 Glass Microspheres 10 Gbq |
| Rigel Pharmaceuticals, INC. | $125.13 | 2022 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $122.22 | 2025 | Vyloy |
| Intuitive Surgical, INC. | $68.84 | 2023 | Da Vinci Surgical System |
| Eisai INC. | $66.33 | 2023 | |
| Caris Mpi, INC. | $25.00 | 2025 | Mi Cancer Seek |
| Davol INC. | $16.41 | 2024 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Steven Cohen listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.